Drug-Polymer Solubility Determination: A New Thermodynamic Model Free from Lattice Theory Assumptions
- 106 Downloads
Traditional methods for estimating drug-polymer solubility either require fast dissolution in the polymeric matrix, rapid re-crystallization kinetics from supersaturated states or derive from regular solution theories. In this work, we present a new method for determining drug solubility, purely based on thermodynamic considerations, that uses only experimental data from DSC for calculations.
The new thermodynamic model presented combines DSC analysis and application of Hess’s law to determine free energies of conversion of binary mixtures to amorphous solid dispersions, free energies of mixing as well as solubility as a function of temperature. The model drug indomethacin and polymers HPMCAS LF, PVP K29/32 and Eudragit EPO were used in these studies.
Free energies were calculated as a function of temperature, for different drug-polymer compositions and the results show that HPMCAS LF solid dispersion with high drug content are less thermodynamically favorable compared to other polymer systems. Solubility of indomethacin in HPMCAS LF, PVP K29/32 and Eudragit EPO was 24, 55 and 56% w/w, respectively, at 25°C.
The thermodynamic model presented has great advantages over traditional methods. It does not require estimation of any interaction parameters, it is almost assumption-free and uses only thermal data for calculations.
KEY WORDSamorphous solid dispersions free energy mixing solubility curve thermodynamics
Active pharmaceutical ingredient
Amorphous solid dispersions
Differential scanning calorimetry
Hypromellose acetate succinate
Spray dried dispersion
ACKNOWLEDGEMENTS AND DISCLOSURES
The authors would like to thank Raquel Borda D’Água for the valuable help with some of the DSC work.
- 6.Murdande SB, Pikal MJ, Shanker RM, Bogner RH. Solubility advantage of amorphous pharmaceuticals: II. Application of quantitative thermodynamic relationships for prediction of solubility enhancement in structurally diverse insoluble pharmaceuticals. Pharm. Res. 2010;27(12):2704–14.Google Scholar
- 11.Flory PJ. Principles of polymer chemistry. Ithaca: Cornell University Press; 1953.Google Scholar
- 13.Rubinstein M, Colby RH. Polymer physics. Oxford: Oxford University Press; 2003.Google Scholar
- 14.Van Krevelen DW, Te Nijenhuis K. Chapter 7 - cohesive properties and solubility. In: Van Krevelen DW, Te Nijenhuis K, editors. Properties of polymers. Fourth ed. Amsterdam: Elsevier; 2009. p. 189–227.Google Scholar
- 15.Hildebrand JH, Scott RL. The solubility of nonelectrolytes. New York: Reinhold Pub. Corp; 1950. x, 488 p. pGoogle Scholar
- 24.Rowe RC, Sheskey PJ, Quinn ME. In: Rowe PJS RC, Quinn ME, editors. Handbook of pharmaceutical excipients. 6th ed. London ; Chicago: Pharmaceutical Press; Washington, DC : American Pharmacists Association; 2009.Google Scholar
- 26.Laitinen R, Priemel PA, Surwase S, Graeser K, Strachan CJ, Grohganz H, et al. Theoretical considerations in developing amorphous solid dispersions. In: Shah N, Sandhu H, Choi DS, Chokshi H, Malick AW, editors. Amorphous solid dispersions: theory and practice. New York, NY: Springer New York; 2014. p. 35–90.CrossRefGoogle Scholar
- 28.Kalogeras IM. A novel approach for analyzing glass-transition temperature vs. composition patterns: application to pharmaceutical compound+polymer systems. Eur. J Pharm Sci. 2011;42(5):470–83.Google Scholar